National trends in use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists by cardiologists and other specialties, 2015 to …
Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like
peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type …
peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type …
Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans …
Background We assessed trends in novel cardiovascular medication utilization in US
Veterans Affairs (VA) for angiotensin receptor-neprilysin inhibitors (ARNI), sodium-glucose …
Veterans Affairs (VA) for angiotensin receptor-neprilysin inhibitors (ARNI), sodium-glucose …
Potential unrealized mortality benefit of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transport‐2 inhibitors: A report from the Veterans Health …
T Salahuddin, V Richardson… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To assess the unrealized potential of glucagon‐like peptide‐1 receptor agonist (GLP‐
1RA) or sodium‐glucose co‐transport‐2 inhibitor (SGLT2i) use to reduce mortality in …
1RA) or sodium‐glucose co‐transport‐2 inhibitor (SGLT2i) use to reduce mortality in …